Key Points
- Director Ezra Friedberg sold 558 shares of Pelthos Therapeutics on July 2 at an average price of $26.09, totaling about $14,558, and still holds 81,042 shares after the trade.
- Pelthos Therapeutics recently reported a quarterly EPS loss of $3.09 on revenue of $10.91 million, while analysts expect the company to post -12.63 EPS for the full year.
- Despite the losses, Wall Street sentiment remains constructive: analysts have a Moderate Buy consensus with an average price target of $55.80, and institutional ownership stands at 77.96%.
Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS - Get Free Report) Director Ezra Friedberg sold 558 shares of Pelthos Therapeutics stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $26.09, for a total transaction of $14,558.22. Following the transaction, the director directly owned 81,042 shares in the company, valued at $2,114,385.78. This trade represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Pelthos Therapeutics Stock Performance
PTHS stock opened at $24.60 on Wednesday. The company has a market cap of $85.61 million, a price-to-earnings ratio of -1.19 and a beta of 3.10. The firm's fifty day simple moving average is $26.77. Pelthos Therapeutics Inc. has a 52 week low of $16.09 and a 52 week high of $37.50. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.86 and a current ratio of 2.79.
Pelthos Therapeutics (NYSEAMERICAN:PTHS - Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share (EPS) for the quarter. The business had revenue of $10.91 million for the quarter. As a group, analysts forecast that Pelthos Therapeutics Inc. will post -12.63 EPS for the current year.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on PTHS shares. Cantor Fitzgerald started coverage on shares of Pelthos Therapeutics in a report on Wednesday, April 1st. They issued an "overweight" rating and a $50.00 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $60.00 price target on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Zacks Research raised shares of Pelthos Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 24th. Finally, Oppenheimer raised their target price on Pelthos Therapeutics from $62.00 to $66.00 and gave the stock an "outperform" rating in a research note on Friday, May 15th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $55.80.
Get Our Latest Stock Report on Pelthos Therapeutics
Institutional Investors Weigh In On Pelthos Therapeutics
A number of large investors have recently modified their holdings of the stock. Persistent Asset Partners Ltd increased its position in shares of Pelthos Therapeutics by 150.0% during the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company's stock valued at $186,000 after buying an additional 3,604 shares during the period. Millennium Management LLC purchased a new position in shares of Pelthos Therapeutics during the 4th quarter worth approximately $343,000. Pale Fire Capital SE raised its position in shares of Pelthos Therapeutics by 59.5% in the 1st quarter. Pale Fire Capital SE now owns 12,919 shares of the company's stock worth $271,000 after acquiring an additional 4,819 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Pelthos Therapeutics by 31.9% in the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company's stock valued at $422,000 after purchasing an additional 3,295 shares during the period. Finally, Knott David M Jr boosted its position in shares of Pelthos Therapeutics by 215.5% during the fourth quarter. Knott David M Jr now owns 19,281 shares of the company's stock valued at $598,000 after purchasing an additional 13,169 shares in the last quarter. Institutional investors own 77.96% of the company's stock.
About Pelthos Therapeutics
(
Get Free Report)
We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
